@Icegoddess wrote:
Just heard on the news that Pfizer has had a hiccup in their manufacturing and that the number of initial doses of their Covid vaccine to the US will be cut in half.
Or they increased their commitment to Britain after getting approval there first and have less for everyone else. A 50% reduction is not a hiccup; it's real cause for concern with the company. Pfizer is a major player in the pharma world, and this requires investigation. If it's really a production problem, what else is amiss on that end?
From what I heard on NPR yesterday, AstraZeneca's vaccine won't be coming to the US at all (if approved here), at least initially. AZ is going to address the needs of the poorer countries that are being cut out of the mRMA vaccines. (I believe I heard that Moderna is committing all of its vaccine to the US, if it's approved.) Of course, poorer countries are less likely to have the infrastructure that could support the ridiculous storage requirements of Pfizer's vaccine. The handling of AZ's vaccine is far more reasonable and customary.
I sure hope no aspect of EUAs are going to be predicated on purported availability of the vaccine, and I really hope the fine minds going over the data will be scouring them for things that don't square, or holes.